6. Krueger GG, O’Reilly MA, Weidner M, Dromgoole SH, Killey FP. Comparative efficacy of once-daily flurandrenolide tape versus twice-daily diflorasone diacetate ointment in the treatment of psoriasis. J Am Acad Dermatol 1998;38:186-90.
7. Bruner CR, Feldman SR, Ventrapragada M, Fleischer AB Jr. A systematic review of adverse effects associated with topical treatments for psoriasis. Dermatol Online J 2003;9:2.
8. Linden KG, Weinstein GD. Psoriasis: current perspectives with an emphasis on treatment. Am J Med 1999;107:595-605.
9. Long CC, Finlay AY. The finger-tip unit—a new practical measure. Clin Exp Dermatol 1991;16:444-7.
10. Brown KK, Rehmus WE, Kimball AB. Determining the relative importance of patient motivations for nonadherence to topical corticosteroid therapy in psoriasis. J Am Acad Dermatol 2006;55:607-13.
11. Feldman SR, Horn EJ, Balkrishnan R, Basra MK, Finlay AY, McCoy D, et al. Psoriasis: improving adherence to topical therapy. J Am Acad Dermatol 2008;59:1009-16.
©Johnson & Johnson Warnings
Two major immune system genes under investigation are interleukin-12 subunit beta ( IL12B ) on chromosome 5q , which expresses interleukin-12B; and IL23R on chromosome 1p, which expresses the interleukin-23 receptor, and is involved in T cell differentiation. Interleukin-23 receptor and IL12B have both been strongly linked with psoriasis.  T cells are involved in the inflammatory process that leads to psoriasis.  These genes are on the pathway that upregulate tumor necrosis factor-α and nuclear factor κB , two genes involved in inflammation.  Recently, the first gene directly linked to psoriasis has been identified. A rare mutation in the gene encoding for the CARD14 protein plus an environmental trigger was enough to cause plaque psoriasis (the most common form of psoriasis).